查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1856758

次世代定序儀CLIA實驗室服務市場（按服務類型、應用、最終用戶、技術平台和樣本類型分類）—全球預測，2025-2032年

Next Generation Sequencing CLIA Laboratory Services Market by Service Type, Application, End User, Technology Platform, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，次世代定序儀CLIA 實驗室服務市場將成長至 192.1 億美元，複合年成長率為 13.89%。

主要市場統計數據
基準年 2024 67.8億美元
預計年份：2025年 77.1億美元
預測年份：2032年 192.1億美元
複合年成長率 (%) 13.89%

本書對塑造CLIA認證的下一代定序實驗室服務的商業實踐和策略要務進行了引人入勝的介紹。

隨著新一代定序 (NGS) 方法日益融入常規臨床工作流程，臨床分子診斷領域正進入加速成熟階段。本執行摘要全面而實用地闡述了 CLIA 認證的 NGS化驗服務的演變歷程、將再形成服務交付模式的曲折點，以及領導者為保持競爭力必須考慮的戰略選擇。本文建構了臨床EXOME、標靶基因panel和全基因組策略與不斷變化的支付方預期、日益嚴格的監管審查以及對精準醫療日益成長的需求並存的商業格局。

前瞻性地整合技術、監管和營運方面的變革，重新定義臨床下一代定序服務的交付和夥伴關係。

在多種因素的共同推動下，CLIA化驗服務與新一代定序技術的整合正經歷著一場變革。技術進步降低了高效能定序的門檻，同時也增加了分析的複雜性，迫使實驗室快速迭代檢測設計、驗證框架和資訊學流程。新的定序平台和改進的化學方法正在改變人們對通量經濟性和數據品質的考量，導致臨床檢測的選擇面臨許多挑戰，例如靶向panel、EXOME組測序和全基因組檢測。

對近期關稅調整將如何重塑臨床NGS實驗室的採購韌性、業務連續性和供應商策略進行深入分析

美國將於2025年實施新的關稅，將對依賴全球供應鏈的CLIA認證的下一代定序實驗室產生即時且連鎖的影響。進口試劑、耗材和儀器零件的關稅將增加單位成本，並使長期採購計畫更加複雜。先前已根據可預測的供應商價格最佳化成本結構的實驗室，需要評估其成本基礎對關稅波動的敏感性，並考慮避險策略、多供應商採購和近岸外包等措施來降低風險。

深入分析決定服務類型、臨床用途、最終用戶、平台技術以及操作和解讀複雜性的樣本考慮因素。

深入的細分揭示了不同服務類型、應用、最終用戶、技術平台和樣本類型在臨床價值和操作複雜性方面的差異。不同的服務類型—臨床EXOME定序、標靶基因panel檢測和全基因定序—展現出不同的驗證負擔和臨床報告要求。臨床EXOME序分為成人和EXOME，需要專門的解讀流程以及不同的知情同意和變異註釋實踐；而靶向基因panel檢測，例如癌症、心血管疾病和神經系統疾病panel檢測，則提供了以臨床效用為重點的可擴展管道。在癌症panel檢測中，血液腫瘤panel和固體癌panel之間的區別決定了檢體處理要求和生物資訊學工作流程的差異，這要求實驗室明確滿足這些需求。

對世界主要地區臨床基因組學服務的監管細微差別、採購動態和招募管道進行區域分析

在美洲、中東和非洲以及亞太地區，地域動態持續影響定序平台的取得、試劑供應鏈、監管解讀和臨床應用率，從而為各地區的實驗室制定了不同的策略重點。在美洲，綜合醫療體系和先進的腫瘤治療中心推動了對伴隨診斷和複雜測序服務的需求，而法規環境則側重於CLIA認證和與支付方的合作，以實現臨床認可和規模化應用。

深入分析決定臨床定序服務競爭優勢的供應商定位、整合解決方案策略和夥伴關係模式

主要企業之間的競爭動態取決於其技術組合的廣度、全球生產和供應的韌性、試劑和耗材生態系統，以及生物資訊學和臨床報告支援的深度。領先的定序平台供應商不僅在讀取準確性和通量方面展開競爭，還在下游服務方面競爭，例如檢測試劑盒、參考資料資料庫和整合資訊學，這些服務能夠縮短臨床驗證的時間並降低成本。平台供應商與診斷實驗室之間的策略夥伴關係，透過將驗證路徑與供應保障相結合，正在加速檢測方法的普及應用。同時，投資於試劑可靠性和​​本地化生產的企業將在供應緊張時期獲得營運優勢。

針對實驗室主管，制定可操作的策略重點，重點在於採購彈性、臨床差異化和可擴展的卓越營運。

產業領導者必須採取雙管齊下的策略，在短期營運韌性和長期臨床差異化之間取得平衡。首先，優先考慮供應商多元化和長期合約安排，以抵禦供應鏈不穩定和關稅的影響。這包括評估替代供應商、建立本地製造夥伴關係以及製定能夠維持臨床連續性的庫存策略。其次，投資於模組化自動化和標準化品質體系，以加快檢測驗證速度、降低錯誤率並支持可擴展的通量，同時確保臨床解讀的嚴謹性。

採用透明的調查方法，結合主要相關人員訪談、技術檢驗審查和情境壓力測試，以提供可操作的實用見解。

本研究結合了實驗室負責人、平台供應商、臨床相關人員和相關領域專家的訪談，以及對監管指南、同行評審文獻和供應商技術文件的系統性回顧，從而提供全面且可操作的評估。調查方法強調三角驗證：定性訪談提供營運方面的見解，技術檢驗和方案審查揭示檢測性能的限制，平台規格的比較分析揭示與臨床部署相關的權衡取捨。

總結性報告重點闡述了策略執行、供應商韌性和臨床證據管道如何幫助臨床基因組醫學服務的持續成長。

總而言之，CLIA認證的下一代定序實驗室服務正處於曲折點，技術進步、供應鏈動態、監管預期以及臨床應用模式的轉變既帶來了挑戰，也帶來了機會。那些積極提升採購韌性、投資強大的生物資訊學解讀框架、並與平台供應商和臨床相關人員建立夥伴關係的實驗室，更有能力將技術能力轉化為可靠且具有臨床應用價值的服務。標靶基因組定序、EXOME序和全基因組定序之間的相互作用，需要一種能夠將檢測方法的選擇與臨床效用、運作能力和監管要求相匹配的綜合思維。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合自動化和人工智慧驅動的生物資訊流程，用於高效能臨床定序
  • 利用液態切片擴大NGS檢測規模，實現腫瘤微量殘存疾病的即時監測
  • 在不同人群中實施藥物基因組學NGS檢測以實現個人化藥物治療管理
  • 採用長讀長定序技術提高遺傳疾病診斷中結構變異的偵測率
  • 開發快速的樣本到報告NGS工作流程，以支持突發感染疾病疫情應對
  • CLIA 合規參考物質的標準化和實驗室間 NGS 檢測驗證的能力驗證

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章次世代定序儀CLIA 實驗室服務市場（依服務類型分類）

  • 臨床EXOME定序
    • 成人外EXOME
    • 兒科外EXOME
  • 標靶基因檢測
    • 癌症小組
      • 血液學檢查
      • 固態腫瘤組
    • 心血管專家組
    • 神經系統疾病專家小組
  • 全基因組定序

第9章次世代定序儀CLIA 實驗室服務市場（依應用分類）

  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 遺傳性疾病
    • 一般疾病
    • 罕見疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固態腫瘤
  • 藥物基因體學
  • 生殖醫學
    • 非侵入性產前檢測
    • 胚胎著床前遺傳學檢測

第10章次世代定序儀CLIA 實驗室服務市場（依最終用戶分類）

  • 診斷實驗室
  • 直接面對消費者的測試
  • 醫院診所
  • 研究所

第11章次世代定序儀CLIA實驗室服務市場（依技術平台分類）

  • 華大基因定序平台
    • Bgiseq 500
    • Mgiseq
  • Illumina定序平台
    • MiSeq
    • NextSeq
    • NovaSeq
  • Thermo Fisher定序平台
    • 離子激流 PGM
    • 離子洪流質子

第12章次世代定序儀CLIA 實驗室服務市場（依樣本類型分類）

  • 血
    • 電漿
    • 全血
  • 唾液
  • 組織
    • FFPE
    • 新鮮冷凍

第13章次世代定序儀CLIA 實驗室服務市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章次世代定序儀CLIA 實驗室服務市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國次世代定序儀CLIA實驗室服務市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Foundation Medicine, Inc.
    • Illumina Clinical Services Laboratory, Inc.
    • Natera, Inc.
    • Myriad Genetics, Inc.
    • Fulgent Genetics, Inc.
    • Guardant Health, Inc.
    • Invitae Corporation
    • Veracyte, Inc.
    • Personalis, Inc.
    • Adaptive BIoTechnologies Corporation
Product Code: MRR-C41945B3D381

The Next Generation Sequencing CLIA Laboratory Services Market is projected to grow by USD 19.21 billion at a CAGR of 13.89% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.78 billion
Estimated Year [2025] USD 7.71 billion
Forecast Year [2032] USD 19.21 billion
CAGR (%) 13.89%

A compelling introduction to the operational realities and strategic imperatives reshaping CLIA-certified next generation sequencing laboratory services

The clinical molecular diagnostics landscape is entering a phase of accelerated maturation where next generation sequencing (NGS) methodologies are increasingly embedded in routine clinical workflows. This executive summary introduces a comprehensive and pragmatic view of how CLIA-certified NGS laboratory services are evolving, the technology and operational inflection points reshaping service delivery, and the strategic choices leaders must deliberate to remain competitive. It frames the business context in which clinical exome, targeted gene panels, and whole genome strategies coexist alongside shifting payer expectations, tighter regulatory scrutiny, and rising demand for precision therapeutics.

Transitioning from development to clinical scale requires an integrated perspective that spans technology platform selection, sample logistics, bioinformatics pipelines, and quality management systems. The Introductory section therefore situates readers within the operational realities of accredited laboratories, highlighting how end users-from hospitals to direct-to-consumer channels-are changing requisition patterns and expectations for turnaround, interpretive clarity, and clinical utility. By focusing on pragmatic change drivers rather than abstract projections, this section prepares decision-makers to interpret subsequent insights and to prioritize investments that yield measurable clinical and commercial returns.

A forward-looking synthesis of technological, regulatory, and operational shifts redefining clinical next generation sequencing service delivery and partnerships

The landscape for CLIA laboratory services powered by next generation sequencing is undergoing transformative shifts driven by several converging forces. Technological progress is lowering the barrier to high-throughput sequencing while simultaneously increasing analytical complexity, compelling laboratories to iterate rapidly on assay design, validation frameworks, and informatics pipelines. Newer sequencing platforms and chemistry refinements are changing throughput economics and data quality considerations, which in turn affect clinical assay choices between targeted panels, exome approaches, and whole genome testing.

Alongside technology, regulatory and reimbursement environments are evolving. Laboratories are adapting to more stringent validation expectations, transparency around variant interpretation, and the need for robust clinical evidence to support diagnostic claims. Payer policies are increasingly focused on demonstrable clinical utility and value-based outcomes, prompting laboratories to emphasize assay standardization, clinical reporting consistency, and longitudinal data collection. Concurrently, the rise of precision oncology and the integration of genomic data into electronic health records are driving tighter collaboration between diagnostic providers, hospitals, and therapeutics developers, creating new service models such as companion diagnostics and longitudinal genomic surveillance.

Operationally, workforce constraints and the need for specialized bioinformatics expertise are catalyzing partnerships with external data providers and software vendors, while quality accreditation and scalability considerations drive laboratories to invest in automation, laboratory information management systems, and cloud-enabled pipelines. Taken together, these shifts mandate a strategic balancing act: adopting innovations that deliver clinical differentiation while ensuring compliance, cost control, and reproducibility in high-volume, regulated environments.

A rigorous analysis of how recent tariff adjustments reshape procurement resilience, operational continuity, and supplier strategies for clinical NGS laboratories

The implementation of new tariff measures in the United States in 2025 introduces immediate and cascading implications for CLIA-certified next generation sequencing laboratories that rely on global supply chains. Tariffs on imported reagents, consumables, and equipment components increase unit costs and complicate long-term procurement planning. Laboratories that previously optimized cost structures around predictable vendor pricing must now evaluate the sensitivity of their cost base to duty fluctuations and consider hedging strategies, multi-sourcing, or nearshoring to mitigate exposure.

Supply chain disruptions are another direct consequence, with extended lead times and allocation risks prompting laboratory managers to reassess inventory policies, safety stock levels, and supplier contracts. In certain instances, laboratories may face prioritization dilemmas when critical reagents or platform components become constrained, forcing a re-evaluation of test menus, throughput commitments, and clinical prioritization frameworks. These operational trade-offs have implications for turnaround time commitments and customer relationships, particularly for high-acuity services such as oncology panels and prenatal diagnostics.

The tariff environment also reshapes competitive positioning. Vendors with diversified manufacturing footprints or domestic production capabilities gain relative advantage, while smaller suppliers dependent on cross-border supply chains may experience margin compression or exit pressures. For laboratories, this means procurement strategies must increasingly incorporate supplier resilience metrics and total landed cost analyses rather than purely unit price comparisons. Additionally, the tariff context incentivizes collaborative approaches with sequencing platform manufacturers and reagent suppliers to secure long-term supply agreements, co-developed pricing models, or localized manufacturing arrangements that preserve service continuity and cost predictability.

Regulatory and compliance frameworks intersect with tariffs in nuanced ways. Changes to import regimes can affect lead times for validated components, necessitating revalidation efforts where alternates or substitute reagents are introduced. Laboratories must therefore build flexible validation pathways and ramp testing protocols that allow controlled substitution without compromising clinical integrity. In sum, the 2025 tariff adjustments force a strategic reorientation across procurement, operations, quality assurance, and commercial engagement to sustain service reliability and maintain margins under greater supply-chain volatility.

A granular exploration of service type, clinical application, end user, platform technology, and sample considerations that determine operational and interpretive complexity

Insightful segmentation illuminates where clinical value and operational complexity intersect across service type, application, end user, technology platform, and sample type. Service type distinctions among clinical exome sequencing, targeted gene panel testing, and whole genome sequencing reveal different validation burdens and clinical reporting demands; clinical exome efforts split between adult and pediatric exomes require specialized interpretive pipelines and distinct consent and variant curation practices, while targeted gene panels such as cancer, cardiovascular, and neurological disorder panels present scalable pathways for focused clinical utility. Within cancer panels, the distinction between hematologic panels and solid tumor panels creates divergent specimen processing requirements and bioinformatics workflows that laboratories must explicitly address.

Application-level segmentation underscores varied clinical evidence needs and specimen workflows. Infectious disease testing divides into bacterial and viral workflows with unique nucleic acid extraction and contamination control considerations, whereas inherited disease testing spans common conditions suitable for higher-throughput approaches and rare disease analyses that demand deep variant curation and multidisciplinary case review. Oncology applications bifurcate into hematologic malignancies and solid tumors, each with differing tissue handling demands and variant interpretation frameworks. Reproductive health applications, ranging from noninvasive prenatal testing to preimplantation genetic testing, impose stringent pre-analytic controls and counseling pathways that laboratories must operationalize.

End user segmentation differentiates service delivery models and commercial interfaces. Diagnostic laboratories, direct-to-consumer testing channels, hospitals and clinics, and research institutes each present unique requisition workflows, reporting expectations, and compliance obligations, requiring laboratories to calibrate client service models accordingly. Technology platform choices among BGI, Illumina, and Thermo Fisher sequencing platforms necessitate vendor-specific validation strategies and throughput planning; within these families, instrument variants such as Bgiseq 500, Mgiseq, MiSeq, NextSeq, NovaSeq, and Ion Torrent models introduce discrete technical and logistical considerations. Sample type segmentation across blood, saliva, and tissue embodies divergent pre-analytic and storage needs, where blood subsets like plasma versus whole blood and tissue formats such as FFPE versus fresh frozen demand tailored extraction and quality assessment procedures. Collectively, these layered segments define the operational playbook laboratories must design to ensure assay reliability, interpretive clarity, and fit-for-purpose clinical deployment.

A regional analysis of regulatory nuance, procurement dynamics, and adoption pathways shaping clinical genomic services across major global regions

Geographic dynamics continue to shape access to sequencing platforms, reagent supply chains, regulatory interpretations, and clinical adoption rates across the Americas, Europe Middle East & Africa, and Asia-Pacific, creating differentiated strategic priorities for laboratories operating in each region. In the Americas, integrated health systems and pockets of advanced oncology care drive demand for companion diagnostics and high-complexity sequencing services, while the regulatory environment emphasizes CLIA accreditation and payer engagement to achieve clinical acceptance and scaling.

Across Europe, the Middle East and Africa, heterogeneity in regulatory frameworks and reimbursement policies generates a patchwork market where laboratories must navigate divergent national requirements and data protection regimes. This environment favors flexible service models, partnerships with regional reference labs, and investments in localized clinical evidence to support adoption. In the Asia-Pacific region, rapid platform uptake, significant local manufacturing presence, and ambitious public health sequencing initiatives are catalyzing growth, but laboratories must manage complex logistics, multilingual reporting requirements, and variable reimbursement mechanisms to translate capability into sustainable clinical services.

The regional differences also influence talent availability, automation adoption, and laboratory consolidation trends. Markets with constrained skilled bioinformatics and clinical genetics capacity often rely more heavily on centralized reference labs or cloud-based interpretive services, whereas regions with concentrated specialist centers can support decentralized offerings and closer hospital-laboratory integration. Understanding regional regulatory nuances, procurement cycles, and clinical referral patterns enables laboratories to tailor go-to-market strategies that align with local demand signals and operational realities.

An in-depth look at vendor positioning, integrated solution strategies, and partnership models that determine competitive advantage in clinical sequencing services

Competitive dynamics among key companies are defined by technology portfolio breadth, global manufacturing and supply resilience, reagent and consumable ecosystems, and the depth of bioinformatics and clinical reporting support. Leading sequencing platform providers compete not only on read accuracy and throughput but also on downstream services such as assay kits, reference databases, and integrated informatics offerings that reduce the time and cost to clinical validation. Strategic partnerships between platform vendors and diagnostic laboratories accelerate assay adoption by aligning validation pathways and supply assurances, while companies investing in reagent reliability and localized production gain operational advantages under constrained supply conditions.

In parallel, companies that offer integrated solutions encompassing sample-to-report workflows, regulatory support, and clinician-facing interpretive tools are increasingly valued by laboratories seeking to shorten deployment timelines and minimize internal development overhead. The emergence of specialized players delivering curated variant databases, clinical decision support, and regulatory-ready documentation creates an ecosystem where laboratories can assemble best-of-breed components or adopt end-to-end solutions depending on strategic priorities. Competitive differentiation also arises from services tailored to high-value clinical applications such as oncology and reproductive health, where the ability to demonstrate clinical validity, report clarity, and actionable recommendations influences purchasing and referral decisions.

Finally, nimble vendors that provide flexible commercial models-subscription-based informatics, reagent-as-a-service, or collaborative validation programs-are well-positioned to support laboratories through technology transitions and regulatory change. As consolidation and strategic alliances continue, laboratories should evaluate partners based on technical performance, supply chain resilience, and the capacity to co-develop clinical workflows that align with institutional objectives.

Actionable strategic priorities for laboratory executives focused on procurement resilience, clinical differentiation, and scalable operational excellence

Industry leaders must pursue a dual strategy that balances near-term operational resilience with long-term clinical differentiation. First, prioritize supplier diversification and long-term contractual arrangements to protect against supply chain volatility and tariff impacts; this includes evaluating alternative vendors, localized manufacturing partnerships, and inventory strategies that preserve clinical continuity. Second, invest in modular automation and standardized quality systems that accelerate assay validation, reduce error rates, and support scalable throughput without sacrificing clinical interpretive rigor.

Third, strengthen bioinformatics and variant interpretation capabilities through a combination of internal talent development and external partnerships, ensuring reproducible pipelines, transparent curation policies, and clinician-friendly reporting. Fourth, deepen engagement with payers and clinicians to build evidence of clinical utility and pathway integration, focusing on high-impact applications such as oncology panels and reproductive health testing where diagnostic decisions directly inform care. Fifth, adopt flexible commercial models and customer support offerings that align with different end-user expectations-from hospitals requiring integrated EHR reporting to direct-to-consumer channels seeking simplified results and counseling frameworks.

Finally, embed regulatory foresight into strategic planning by cultivating capabilities for rapid revalidation, documentation management, and audit readiness. Leaders should also consider collaborative approaches with platform vendors and peer laboratories to share validation burden, harmonize reporting standards, and accelerate adoption of best practices. These combined actions will enable organizations to preserve service reliability, enhance clinical credibility, and capture opportunities created by evolving care pathways and technology advances.

A transparent methodology combining primary stakeholder interviews, technical validation review, and scenario stress-testing to inform operationally actionable insights

This research synthesizes primary engagements with laboratory leaders, platform vendors, clinical stakeholders, and subject-matter experts, combined with systematic review of regulatory guidance, peer-reviewed literature, and vendor technical documentation to produce a comprehensive and practical assessment. The methodology emphasizes triangulation: qualitative interviews contextualize operational realities, technical validations and protocol reviews illuminate assay performance constraints, and comparative analyses of platform specifications identify trade-offs relevant to clinical deployment.

Quality assurance in the research process included cross-validation of interpretive frameworks with practicing clinical geneticists and laboratory directors, and scenario stress-testing of procurement and supply-chain responses to tariff changes. The research also incorporated detailed mapping of sample workflows across specimen types-blood, saliva, and tissue-to identify pre-analytic vulnerabilities and mitigation strategies. Where possible, evidence was prioritized that reflects clinical workflows and regulatory compliance needs rather than marketing claims, ensuring that recommendations are implementable and aligned with accreditation requirements.

Analytical approaches focused on decomposing operational costs into process-level activities, evaluating validation timelines for different assay classes, and assessing vendor resilience across manufacturing footprints. Throughout, confidentiality and ethical considerations guided primary data collection, and methodologies were designed to be transparent and reproducible so that organizations can adapt the approach for their internal audits and strategic planning exercises.

A conclusive synthesis emphasizing strategic execution, supplier resilience, and clinical evidence pathways that enable sustainable growth in clinical genomics services

In conclusion, CLIA-certified next generation sequencing laboratory services are at an inflection point where technology advances, supply-chain dynamics, regulatory expectations, and shifting clinical adoption patterns converge to create both challenges and opportunities. Laboratories that proactively address procurement resilience, invest in robust bioinformatics and interpretive frameworks, and cultivate partnerships with platform vendors and clinical stakeholders will be best positioned to translate technological capability into reliable, clinically actionable services. The interplay between targeted panels, exome approaches, and whole genome testing requires a portfolio mindset that aligns assay choice with clinical utility, operational capacity, and regulatory obligations.

Furthermore, regional dynamics and tariff-related supply risks underscore the necessity for flexible validation pathways and diversified sourcing strategies. Companies and laboratories that prioritize quality systems, clinician engagement, and payer evidence-building can accelerate adoption while maintaining compliance and trust. Ultimately, success in this sector will hinge on disciplined execution across laboratory processes, strategic supplier relationships, and a relentless focus on delivering clear clinical value that integrates seamlessly into patient care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of automation and AI-driven bioinformatics pipelines for high throughput clinical sequencing
  • 5.2. Expansion of liquid biopsy-based NGS assays for real-time monitoring of minimal residual disease in oncology
  • 5.3. Implementation of pharmacogenomic NGS testing for personalized medication therapy management in diverse populations
  • 5.4. Adoption of long-read sequencing technologies to improve detection of structural variants in genetic disease diagnostics
  • 5.5. Development of rapid sample-to-report NGS workflows to support urgent infectious disease outbreak response
  • 5.6. Standardization of CLIA-compliant reference materials and proficiency testing for NGS assay validation across labs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next Generation Sequencing CLIA Laboratory Services Market, by Service Type

  • 8.1. Clinical Exome Sequencing
    • 8.1.1. Adult Exome
    • 8.1.2. Pediatric Exome
  • 8.2. Targeted Gene Panel Testing
    • 8.2.1. Cancer Panels
      • 8.2.1.1. Hematologic Panels
      • 8.2.1.2. Solid Tumor Panels
    • 8.2.2. Cardiovascular Panels
    • 8.2.3. Neurological Disorder Panels
  • 8.3. Whole Genome Sequencing

9. Next Generation Sequencing CLIA Laboratory Services Market, by Application

  • 9.1. Infectious Disease
    • 9.1.1. Bacterial Infections
    • 9.1.2. Viral Infections
  • 9.2. Inherited Disease
    • 9.2.1. Common Disease
    • 9.2.2. Rare Disease
  • 9.3. Oncology
    • 9.3.1. Hematologic Malignancies
    • 9.3.2. Solid Tumor
  • 9.4. Pharmacogenomics
  • 9.5. Reproductive Health
    • 9.5.1. Noninvasive Prenatal Testing
    • 9.5.2. Preimplantation Genetic Testing

10. Next Generation Sequencing CLIA Laboratory Services Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Direct To Consumer Testing
  • 10.3. Hospitals And Clinics
  • 10.4. Research Institutes

11. Next Generation Sequencing CLIA Laboratory Services Market, by Technology Platform

  • 11.1. BGI Sequencing Platforms
    • 11.1.1. Bgiseq 500
    • 11.1.2. Mgiseq
  • 11.2. Illumina Sequencing Platforms
    • 11.2.1. MiSeq
    • 11.2.2. NextSeq
    • 11.2.3. NovaSeq
  • 11.3. Thermo Fisher Sequencing Platforms
    • 11.3.1. Ion Torrent Pgm
    • 11.3.2. Ion Torrent Proton

12. Next Generation Sequencing CLIA Laboratory Services Market, by Sample Type

  • 12.1. Blood
    • 12.1.1. Plasma
    • 12.1.2. Whole Blood
  • 12.2. Saliva
  • 12.3. Tissue
    • 12.3.1. Ffpe
    • 12.3.2. Fresh Frozen

13. Next Generation Sequencing CLIA Laboratory Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Next Generation Sequencing CLIA Laboratory Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Next Generation Sequencing CLIA Laboratory Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Foundation Medicine, Inc.
    • 16.3.2. Illumina Clinical Services Laboratory, Inc.
    • 16.3.3. Natera, Inc.
    • 16.3.4. Myriad Genetics, Inc.
    • 16.3.5. Fulgent Genetics, Inc.
    • 16.3.6. Guardant Health, Inc.
    • 16.3.7. Invitae Corporation
    • 16.3.8. Veracyte, Inc.
    • 16.3.9. Personalis, Inc.
    • 16.3.10. Adaptive Biotechnologies Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO